Comparisons on efficacy and cost between two kinds of adefovir dipivoxil in 48 weeks treatment of chronic hepatitis B patients

Objective To evaluate the efficacy and cost between homemade adefovir dipivoxil(AGanDing) and Hepsera in 48 weeks treatment of patients with HBeAg-positive chronic hepatitis B.Methods Total of 90 patients with HBeAg-positive chronic hepatitis B were recruited for research who never received nucleoside analogues treatment before.They were divided into AGanDing group including 41 cases and Hepsera group including 49 cases.Both groups were administered with adefovir dipivoxil 10 mg per day for 48 weeks.Meanwhile,serum HBV DNA level,HBeAg and liver functions were observed.Results There were no differences between two groups in demography and clinical feature.And no difference were found between two groups at week 48 in median reduction in serum HBV DNA level,the rate of ALT normalization and HBeAg seroconversion.But the rate of HBeAg loss in AGanDing group was significantly higher than that in Hepsera group.At the end of treatment,three cases occurred breakthrough in HBV DNA,one of which was in AGanDing group and two in Hepsera group.The cost-effectiveness ratio in rate of ALT normalization,HBV DNA undetectable and HBeAg seroconversion was 120.66,198.25,1308.24 yuan,respectively in Hepsera group,which were higher than that in AGanDing group(60.05,86.74,338.71 yuan,respectively).Conclusions There were no differences between AGanDing group and Hepsera group in rate of ALT normalization and HBV DNA undetectable.But greater rate of HBeAg loss seems to be observed more often in AGanDing group than Hepsera group.The cost-effectiveness ratio of AGanDing group is significantly superior to Hepsera group.